Even though, we for the first time, show in this work, siRNA against CSPG4 can reduce cell viability of osimertinib refractory NSCLC cells, CSPG4 has for long been known to regulate cancer hallmarks in other tumour types, such as malignant melanoma (Price et al. This evidence concerns the gene CSPG4 and non-small cell lung carcinoma.